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PURPOSE. We report the 12-month outcomes of 1140 treatment-näıve eyes with exudative age-
related macular degeneration (wet AMD) who were treated for 12 months with intravitreal
anti-VEGF drugs in routine clinical practice.
METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in
Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments,
outcomes (VA, lesion activity status) and ocular adverse events were recorded in a
prospectively designed electronic database. Index visit characteristics associated with the
12-month VA outcome were identified using mixed effects linear regression.
RESULTS. Mean change in VA in the cohort after 12 months was þ4.7 logMAR letters (95%
confidence interval [CI], 3.4–6.1) with a mean of 7.0 injections. No significant difference was
found in change in VA, or number of injections by type or size of the lesion. Median time to
inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the
12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment
occurred in 1 case from a total of 9162 injections.
CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good
outcomes for wet AMD when used in routine clinical practice.
Keywords: anti-VEGF, observational study, neovascular age-related macular degeneration
While the efficacy of ranibizumab (Lucentis; Novartis,Basel, Switzerland), bevacizumab (Avastin; Hoffman-
LaRoche, Basel, Switzerland), and aflibercept (Eylea; Bayer,
Basel, Switzerland) for exudative age-related macular degener-
ation (wet AMD)1 has been demonstrated convincingly by
tightly controlled phase 3 clinical trials,2–7 it still is not certain
whether the results of these studies will be replicated in the
real world after the new drugs have been approved for general
use. Many patients being treated for wet AMD in the general
community may not have met inclusion criteria of the clinical
trials. Even if they had, a heavy treatment burden on all
involved in routine retinal practice has led to dosing regimens
that are less intensive than those used in the pivotal trials, such
as the pro re nata (PRN) and treat-and-extend regimens.8,9
The Fight Retinal Blindness! (FRB) Project has established a
prospective audit system that can track anonymously outcomes
of treatment of retinal disease, such as wet AMD, in large
numbers of patients treated in routine retinal treatment
centers.10 Here, we describe the 12-month outcomes, including
visual acuity (VA), grading of lesion activity, and adverse events,
for 1140 treatment-naive participants in the FRB! Project wet
AMD audit.
METHODS
Study Design and Setting
This is an observational study utilizing anonymized longitudinal
data from the FRB registry that were captured during routine
clinical practice. All treatment decisions and visit schedules
were entirely at the discretion of the treating physician and
patient. Details of the FRB project data tracking system have
been reported previously.10 The research followed the tenets of
the Declaration of Helsinki. Patients were given information
regarding the project and given the opportunity to opt out of
the project. Each of the three academic core centers from the
Universities of Sydney, Melbourne, and Western Australia
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obtained approval from their respective Human Research
Ethics Committees (HREC) to conduct the project as a quality
assurance activity. Overarching ethical approval for the other
centers was obtained from the HREC of the Royal Australian
and New Zealand College of Ophthalmologists.
Patient data recorded from 27 retinal specialists located
across Australia from January 2006 until September 2012 were
aggregated for analysis. The project began collecting data from
the core centers in Sydney, Melbourne, and Perth, and then
spread to nonacademic retinal services in the capital cities of
most Australian states.
Participants and Variables
Few eligibility criteria were applied beyond treatment-näıve
eyes commencing treatment for wet AMD that had been
diagnosed by their treating ophthalmologist with VA >20
letters. All eyes in the database that commenced treatment
between January 2004 and November 2011 were included in
this analysis, so that all potentially had 12 months of follow-up.
At the index visit, that is the visit at which treatment was
commenced, the study participants’ age; angiographic lesion
criteria, such as lesion type and greatest linear dimension
(GLD); VA (Logarithm of the Minimum Angle of Resolution
[LogMAR], recorded as letters read); choroidal neovasculariza-
tion (CNV) status (active, inactive); along with treatment
history; and treatment decisions (treated or not treated and
name of drug used) were recorded. Investigators were asked to
enter whichever VA reading was best: uncorrected, corrected,
or pinhole. The best VA achieved during each visit was used for
analysis. The judgement of ‘‘active’’ or ‘‘inactive’’ was left to
the investigator’s discretion, thus reflecting real-world prac-
tice. It was suggested that users should grade lesions as active if
there was intra- or subretinal fluid, or any other feature present
that could be attributed to activity of the neovascular lesion.
Follow-up visits recorded subsequent VA, CNV status, all
treatment decisions, and any ocular adverse events. Three
subgroups of interest were prespecified: occult lesions (OC),
minimally classic lesions (MC), and predominantly classic
lesions (PC).
Statistical Methods
For continuous variables means or medians and interquartile
range (Q1, Q3) were computed. Of the patients 17%
contributed both eyes to the study database; when measuring
variation and performing statistical tests at the index visit,
fellow eyes were removed randomly to ensure any possible
intereye correlation would not bias estimates. Formal compar-
isons were made using the nonparametric Kolmogorov-Smirn-
off (KS) test, which is sensitive to any difference in the
underlying distribution of two samples.
The outcomes analysis used data from all eyes that
completed 12 months follow-up, while the safety analysis set
included all available data over 12 months. We also examined
outcomes for eyes that did not complete 12 months of follow-
up due to withdrawal from treatment or loss to follow-up.
Study endpoints included 12-month longitudinal VA, time from
first intravitreal injection to inactivation of CNV, and change in
CNV status over 12 months. Within-eye changes in VA over 12
months were tested using the paired t-test. Longitudinal VA
data were plotted using a Lowess smoothed regression
line.11,12 A mixed effects regression model was fitted to the
longitudinal VA data to examine the effects of lesion type, GLD,
and age on VA at 12 months.
Kaplan-Meier analysis13 was used to examine time from first
injection to inactivation of CNV status. All observed adverse
events were tabulated and reported. Analysis and plots were
done using R version 2.15.0.14
RESULTS
There were 1140 eyes that completed 12 months follow-up
(10,758 visits). The study population was 61% female and the
mean age was 79.3 years (Q1, Q3; 75, 85). Mean VA at the index
visit was 57.1 letters (Q1, Q3; 45, 69, Table 1). Due to the
quality assurance features of the FRB web-based data entry
system, data quality was high for all variables (>99.5%
complete) with the exception of GLD (80% complete) and
lesion type (88% complete).
Treatment Administered
A total of 8013 injections was given to the 1140 eyes that
completed 12 months, a mean (Q1, Q3) of 7.0 (5, 9) injections
per eye (Table 2). The mean number of injections by lesion
type was similar. The majority of injections administered were
ranibizumab (91%) irrespective of lesion type, with the
remainder being bevacizumab. For all lesion types the interval
TABLE 1. Index Visit Characteristics of Eyes That Completed 12
Months of Follow-up and Those That Did Not
Characteristic
12-Month
Completers Noncompleters
Eyes 1140 230
Visits 10,758 1,496
Median days follow-up (Q1,
Q3) – 210 (111, 302)
Mean index VA (Q1, Q3) 57.1 (45, 69) 52.5 (40, 65)
Mean age (Q1, Q3) 79.3 (75, 85) 79.9 (75, 85)
Female, % 61.3 58.3
Median GLD (Q1, Q3) 2000 (1300, 3050) 2315 (1500, 3390)
Lesion type
Occult, n (%) 529 (53.6) 109 (51.4)
Minimally classic, n (%) 211 (21.4) 50 (23.6)
Predominantly classic, n
(%) 171 (17.3) 43 (20.3)
Other, n (%) 76 (7.7) 10 (4.7)
Unclassified, n 163 18
TABLE 2. Injection Frequency and Type Over 12 Months of Follow-up
Occult Min Class Pred Class All
Mean (Q1, Q3) n of injections 7.0 (5, 9) 6.8 (5, 9) 7.1 (5, 9) 7.0 (5, 9)
Median (Q1, Q3) d between injections when active 35 (28, 52) 41 (29, 55) 35 (28, 56) 36 (28, 56)
Median (Q1, Q3) d between injections when inactive 43 (35, 63) 49 (36, 63) 42 (33, 56) 42 (35, 63)
% Ranibizumab injections 91.3% 92.3% 91.4% 91.4%
Min Class, minimally classic; Pred, predominantly.
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between injections was greater when lesions were graded as
inactive than when they were graded as active.
VA and GLD at the Index Visit
There were notable differences in the distributions of VA and
GLD among the lesion type subgroups (Table 3, Fig. 1).15 VA
when starting treatment was lower for the PC classic group
than the OC subgroup (P < 0.0001, KS test) and the MC
subgroup (P¼ 0.01, KS test). GLD was lower in the PC group
than either OC or MC: OC versus PC (P¼0.002), MC versus PC
(P ¼ 0.005), and OC versus MC (P ¼ 0.5, Fig. 1).
Unadjusted 12-Month VA Outcomes
The mean within-eye change in VA was a þ4.7 letter
improvement (95% confidence interval [CI], 3.4–6.1) for the
study population as a whole. Similar clinically relevant mean
improvements were observed for all subgroups (Fig. 2A): OC
þ4.9 letters (95% CI, 2.1–7.1), MC þ4.5 letters (95% CI, 1.9–
7.1), and PC þ5.1 letters (95% CI, 1.9–8.2). The Lowess lines
indicated that all three groups exhibited a monotonic
improvement throughout 12 months (Fig. 2B).
Modelled 12-Month VA Outcomes
Given the observed imbalance at the index visit in VA and
GLD for the 3 subgroups, a mixed effects regression model
was fitted to the longitudinal VA measurements to mitigate
potential confounding influences (Table 4). The model
coefficients for the MC and PC lesions (relative to OC) of
1.3 and 0.5, respectively, indicated that lesion subgroup
had very little effect (<1.5 LogMAR letters) on VA outcomes.
The coefficient for age of 0.03 indicated slightly worse
outcomes with increasing age: a three decade increase in age
was associated with a decreased gain of 1 LogMAR letter after
12 months of treatment. A 1 mm (1000 lm) increase in GLD
was associated with a reduced gain of 0.5 letters. The
coefficient for time indicated an annual mean improvement of
3.1 letters. VA at the index visit was a highly significant
predictor of outcome.
Lesion Activity Over 12 Months
The median time from first intravitreal injection to lesions
being graded as ‘‘inactive’’ was 194 days (95% CI, 174–216, Fig.
3). Of the eyes, 37% were graded persistently as active during
the 12 months of treatment. The median time between
injections was 36 days (Q1, Q3; 28, 56) while the lesions were
graded as ‘‘active’’ and 42 days (Q1, Q3; 35, 63) while graded
‘‘inactive.’’
Eyes That Did Not Complete 12 Months of Follow-
up
A total of 230 eyes (17%) either withdrew from treatment or
were lost to follow-up over the observed 12-month interval
(noncompleters). Median follow-up time for these eyes was
210 days (Q1, Q3; 111, 302). At the index visit, noncompleters
were similar to completers in most respects except for lower
VA (mean 57.1 vs. 52.5, P¼ 0.0004, KS test). The outcomes for
noncompleters are shown in longitudinal profiles in Figure 4.
Safety
Ocular adverse events observed over 12 months follow-up are
summarized in Table 5. The most common adverse event was
patient-reported postinjection pain (45 instances). Two in-
stances of infectious endophthalmitis were reported out of a
total of 9162 injections.
DISCUSSION
This analysis of outcome data that were collected prospectively
and continuously from patients receiving treatment for
TABLE 3. Index Visit VA and GLD With VA Change After 12 Months
Occult Min Class Pred Class All
Mean (Q1, Q3) VA index visit 58.9 (50, 70) 57.1 (44, 67) 51.8 (37, 64) 57.1 (45, 69)
Mean 12 mo VA change (95% CI*) 4.9 (2.1–7.1) 4.5 (1.9–7.1) 5.1 (1.9–8.2) 4.7 (3.4–6.1)
Median (Q1, Q3) index GLD 2080 (1255, 3200) 2015 (1525, 3030) 1740 (1065, 2555) 2000 (1300, 3050)
* Bias corrected and accelerated bootstrap 95% CIs.15
FIGURE 1. Density plots of VA (left) and greatest linear dimension (right) at the index visit by lesion type.
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exudative AMD has produced a number of observations on the
use and outcomes of intravitreal therapy in routine practice.
Mean VA of the main cohort improved significantly by þ4.7
logMAR letters over the first 12 months of treatment with a
mean of 7 injections. The mean VA of predominantly classic
lesions improved slightly more than that of the minimally
classic or occult groups, although eyes with predominantly
classic lesions had lower VA at the index visit. Otherwise,
lesion type and size made little difference to the pattern of
treatment outcomes, of which the strongest predictor was VA
at the first treatment visit. The median time to first grading of
lesions as inactive was 194 days, with 37% still active at 12
months. Safety findings were similar to previous reports. These
findings indicated that VEGF inhibitors achieve good outcomes
for wet AMD when used in routine clinical practice.
Several other observational studies of intravitreal therapy
for neovascular AMD have been reported recently. The
Swedish Lucentis Quality Registry found a good improvement
in VA after 3 injections of ranibizumab, but this subsequently
dropped back to pretreatment levels.16 Patients in that study
received a mean of only 4.8 injections over 12 months, fewer
than in the present study. Similar results were found by the
WAVE study and an analysis of the German reinjection
scheme.17,18 These studies that recorded lower gains in mean
visual acuities also had a lower mean number of injections.
An improvement in mean VA after the first 12 months of
treatment that was more similar to our results has been
reported by two other observational studies. A gain of 3.2
LogMAR letters was found with a mean of 5.1 injections in the
French Lumiere study of 551 patients.19 Menghini et al.
reported a mean improvement of 5 letters with a mean of 4
injections in 204 eyes.20
An overall mean improvement of 4.7 logMAR letters in the
current report still is somewhat less than was reported in
phase 3 clinical trials of ranibizumab.2,3 However, the
improvements in these studies were measured primarily
against the change of vision in the control groups. Vertepor-
fin-treated eyes had lost a mean of 9.5 letters by 12 months in
ANCHOR, while sham-treated eyes had lost 10.4 letters in
MARINA. Seen in this light, the increase in VA found in the
present analysis of outcomes of treated eyes in routine practice
is reassuring. This was achieved with a mean of 7.0 injections,
significantly more than was given in previously reported
observational studies,16–20 out of potentially 13 that would be
given with a strict monthly regimen. This frequency is similar
to that of the CATT study, in which a mean of 6.9 injections
were given to the ranibizumab PRN group and 7.7 to the
bevacizumab PRN group.5
Median time to grading the lesion as ‘‘inactive’’ was 194
days. Of the lesions 37% were graded consistently as active
throughout the first year of the study. As might be expected,
these eyes received more injections. A related variable,
presence of fluid at the 1-year visit, was reported in 81% of
bevacizumab PRN and 56% of ranibizumab monthly groups of
the CATT study.5 It appears that reasonably good VA outcomes
can be obtained despite many eyes remaining active much or
all of the time.
Lesion characteristics, particularly lesion size (GLD) and
type, did not affect the outcomes of this study significantly.
Lesion type also had little effect on outcomes in retrospective
analyses of MARINA and ANCHOR, in which mixed lesions had
similar outcomes to purely classic or purely occult lesions.21,22
FIGURE 2. Density plot of within group changes at 12 months (left) and fitted Lowess lines showing subgroup changes in VA over 12 months (right).
TABLE 4. Coefficients From Mixed Effects Model Fit to 12-Month
Longitudinal VA Data
Model Coefficient t Value
Index visual acuity 0.9 62.93
Index visit age 0.03 1.00
MC, relative to OC 1.3 2.72
PC, relative to OC 0.5 0.98
GLD 1000 lm 0.5 2.95
1 y follow-up 3.1 6.50 FIGURE 3. Kaplan-Meier plot of time from active lesion first being
graded as inactive.
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Menghini et al. also found no effect of lesion type on visual
outcome after 24 months of treatment in another observational
study.20 In a recent report from Comparison of AMD Treatment
Trials, predominantly or minimally classic versus occult CNV
was not included in the final multivariate model of change in
VA at 1 year because it was not statistically significant.23
Predominantly or minimally classic lesions were associated
independently with less improvement in VA at 1 year in that
study. Similarly, another recent report found no difference in
VA outcome for occult, minimally classic or predominantly
classic lesions in the PIER study.24
The rate of serious adverse events was consistent with
previous experience. Infectious endophthalmitis occurred in 2
patients, an incidence of 2.2 per 10,000 injections. Noninfec-
tious endophthalmitis was reported in 2 more cases. Retinal
detachment occurred in 1 eye, an incidence of 1.1 per 10,000
injections; this is similar to the rate at which retinal
detachments are reported to occur in the general population.25
Mild adverse events appear to be underreported, since there
were only 45 episodes of postinjection pain. This indicates that
registries may not track accurately outcomes that clinicians do
not believe are clinically significant.
This study, like all observational studies, has some
limitations arising from the way in which data were collected.
Subjective criteria, such as lesion activity or lesion type, may
not be graded uniformly in observational studies, since they are
reported by the treating physicians rather than a centralized
Reading Center. Thus, these determinations may have lower
internal validity than in a phase 3 clinical trial, but perhaps
they still are meaningful, since this is how these clinically
important determinations actually are being made in the real
world. The measurement of LogMAR VA, the main outcome, is
reasonably objective. Also, case selection and treatment
regimens in observational studies may be very different to
those of clinical trials and among different ophthalmologists.
Nevertheless, the data presented showed generally consistent
outcomes of treatment regimens, which appeared to be similar
across the different centers (data not shown).
A number of further analyses can be performed on
observational data that we presented here. A study of the
efficacy of different treatment intensities will need to take into
account ‘‘treatment by time’’ interactions (a treatment in the
first 3 months is likely to have a greater effect than a treatment
in the last 3 months), and the possibility that the outcome of
treatment drives treatment intensity, with eyes responding
poorly receiving more treatments than these that respond well,
rather than vice versa. A study of poor responders would need
to include not just the proportion of patients who, for
FIGURE 4. Fitted Lowess lines showing changes in VA over 12 months for noncompleters (A–C) and completers (D).
TABLE 5. Adverse Events
Frequency Injections per AE
Post injection pain reported 45 204
Hemorrhage reducing VA >15 5 –
Retinal detachment 1 9162
Noninfectious endophthalmitis 2 4581
Infectious endophthalmitis 2 4581
RPE tear 12 764
Cataract extraction/other surgery 15 611
RPE, retinal pigment epithelium.
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example, lose 15 letters, but also analysis of their baseline
characteristics, how the loss evolved over time and whether
the causes could be identified by a case by case analysis
referring back to the clinic notes in a selected subgroup.
Treatment patterns and their different efficacies also can be
identified: a pro re nata regimen will be revealed when
treatments are given only when the lesion is graded as active,
while a treat-and-extend regimen will have most treatments
given when the lesion is graded as inactive.
The significance of data from observational studies is that
they provide an indication of what is happening in routine
clinical practice, in contrast to results of phase 3 clinical trials,
which may or may not be achievable in general. The results we
presented of intravitreal therapy for wet AMD are reasonably
good, at least in the Australian centers that chose to
participate. Further research is warranted to determine the
functional implications of persistent activity and whether
cohorts of patients receiving routine treatment do as well as
those in phase 3 studies when they are matched more closely
to participants in those studies.
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singhe); Specialists Eye Group, Glen Waverly, VIC (S. Wickre-
masinghe and L.P. Chow); Eye Institute, Auckland, NZ (P.
Hadden); ADHB, Auckland, NZ (D. Squirrell); Milford Eye
Clinic, Auckland, NZ (D. Squirrell); University Hospital Zurich,
University of Zurich, Zurich Switzerland (D. Barthelmes);
Retina Specialist Auckland, NZ (D. Sharp, R. Barnes and P.
Hadden).
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